Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: Converging evidence from phase II trials

PURPOSE: Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Ellingson, Benjamin M., Gerstner, Elizabeth R., Smits, Marion, Huang, Raymond Y., Colen, Rivka, Abrey, Lauren E., Aftab, Dana T., Schwab, Gisela M., Hessel, Colin, Harris, Robert J., Chakhoyan, Ararat, Gahrmann, Renske, Pope, Whitney B., Leu, Kevin, Raymond, Catalina, Woodworth, Davis C., de Groot, John, Wen, Patrick Y., Batchelor, Tracy T., van den Bent, Martin J., Cloughesy, Timothy F.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626594/
https://ncbi.nlm.nih.gov/pubmed/28655794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2844
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars